MMAF Hydrochloride (Synonyms: Monomethylauristatin F hydrochloride) |
Catalog No.GC36633 |
MMAF(Monomethylauristatin F) 염산염은 강력한 튜불린 중합 억제제이며 항종양제로 사용됩니다. MMAF 염산염은 Vorsetuzumab mafodotin 및 SGN-CD19A와 같은 항체-약물 접합체(ADC)의 세포 독성 성분으로 널리 사용됩니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1415246-68-2
Sample solution is provided at 25 µL, 10mM.
MMAF hydrochloride (Monomethylauristatin F Hydrochloride) is an antitubulin agent that inhibit cell division; inhibits H3397 cell growth with an IC50 of 105 nM. IC50: 119 nM (Cytotoxicity, Karpas 299 cell), 105 nM (Cytotoxicity, H3396 cell), 257 nM (Cytotoxicity, 786-O cell), 200 nM (Cytotoxicity, Caki-1, cell)[1]
MMAF shows in vitro cytotoxicity against a panel of cell lines. The IC50 values for Karpas 299, H3396, 786-O and Caki-1 are 119, 105, 257, and 200 nM, respectively. Targeted MMAF is much more potent than the free drug, and that cAC10 conjugates of MMAF display pronounced activities. On a molar basis, the cAC10-L1-MMAF4 is an average of over 2200-fold more potent than free MMAF and is active on all the CD30-positive cell lines tested[1].
The maximum tolerated dose in mice of MMAF (>16 mg/kg) is much higher than MMAE (1 mg/kg). cAC10-L1-MMAF4 has an MTD of 50 mg/kg in mice and 15 mg/kg in rats. The corresponding cAC10-L4-MMAF4 ADC was much less toxic, having MTDs in mice and rats of >150 mg/ kg and 90 mg/kg in rats, respectively[1].
[1]. Doronina SO, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006 Jan-Feb;17(1):114-24.
Average Rating: 5
(Based on Reviews and 4 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *